Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Lars Buschhorn"'
Autor:
Lars Buschhorn, Dorett I. Odoni, Johanna Geuder, Timo O. Odinius, Celina V. Wagner, Stefanie Jilg, Ulrike Höckendorf, Adam Wahida, Matthias Schlesner, Andreas Reiter, Mohamad Jawhar, Philipp J. Jost
Publikováno v:
Haematologica, Vol 108, Iss 11 (2023)
Externí odkaz:
https://doaj.org/article/bc1a15f1f759423bb9cf447e09be5ed2
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
Autor:
Stefanie Jilg, Richard T. Hauch, Johanna Kauschinger, Lars Buschhorn, Timo O. Odinius, Veronika Dill, Catharina Müller-Thomas, Tobias Herold, Peter M. Prodinger, Burkhard Schmidt, Dirk Hempel, Florian Bassermann, Christian Peschel, Katharina S. Götze, Ulrike Höckendorf, Torsten Haferlach, Philipp J. Jost
Publikováno v:
Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-5 (2019)
Abstract Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which on
Externí odkaz:
https://doaj.org/article/df9b0a919cb44a77b92b1bff8cc2854a
Publikováno v:
Clinical Cancer Research. :OF1-OF8
Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led to therapeutics with pan-cancer efficacy. To date,
Publikováno v:
Cancer Discovery. :OF1-OF9
Summary: The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. In that regard, N-of-1 studies emerge as a potential additi
Autor:
Andreas Schneeweiss, Lars Buschhorn
Publikováno v:
Die Radiologie. 63:366-370
Autor:
Lars Buschhorn, Dorett I. Odoni, Johanna Geuder, Timo O. Odinius, Celina V. Wagner, Stefanie Jilg, Ulrike Höckendorf, Adam Wahida, Matthias Schlesner, Andreas Reiter, Mohamad Jawhar, Philipp J. Jost
Publikováno v:
Haematologica.
Not available.
Frequency of tissue-agnostic targets in other additional different tumors (alphabetically arranged) in AACR GENIE v.13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::077bb4874b0bff749347ed9e2219b491
https://doi.org/10.1158/1078-0432.22734076
https://doi.org/10.1158/1078-0432.22734076
Genes most frequently mutated in cases with tissue-agnostic targets in the overall altered population and top 5 cancers with highest number of profiled samples in each alteration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7edd664a19151828c686bb51c7f51e53
https://doi.org/10.1158/1078-0432.22734079
https://doi.org/10.1158/1078-0432.22734079
Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led to therapeutics with pan-cancer efficacy. To date,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62da77281c77960e7c598aba7a82c395
https://doi.org/10.1158/1078-0432.c.6626953.v1
https://doi.org/10.1158/1078-0432.c.6626953.v1
Autor:
Veronika Dill, Celina V. Wagner, Eva C. Keller, Francisco Jose Fernandez-Hernandez, Khalid Shoumariyeh, Timo O. Odinius, Lars Buschhorn, Richard T. Hauch, Christian Suren, Judith S. Hecker, Peter Herhaus, Michael Sandherr, Burkhard Schmidt, Julia Slotta-Huspenina, Florian Bassermann, Ulrike Höckendorf, Stefanie Jilg, Caterina Branca, Sebastian Vosberg, Philipp J. Jost
Publikováno v:
Blood advances.